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SpironolactoneThe steroid hormone aldosterone regulates the reabsorption of water and ions in the kidney and plays a central
role in bloodpressure regulation andhomeostasis. In recent years, the vascular endotheliumhas been established
as an important aldosterone target organwithmajor implications in renal and cardiovascular health and disease.
Different lines of evidence suggest that the calcium- and bicarbonate-activated soluble adenylyl cyclase (sAC) is a
novel mediator of aldosterone signaling in both the kidney and vascular endothelium. This review summarizes
our current understanding of the molecular mechanisms of sAC gene expression regulation in the kidney and
vascular endothelium and outlines the potential clinical implications of sAC in chronic kidney disease and cardio-
vascular disease. This review is part of a special issue entitled: The role of soluble adenylyl cyclase in health and
disease. This article is part of a Special Issue entitled: The role of soluble adenylyl cyclase in health and disease.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
In 1999, the soluble adenylyl cyclase (sAC) (OMIM #605205) was
identiﬁed as a new, distinct and soluble class of mammalian adenylyl
cyclase, insensitive to G protein or forskolin regulation [1]. The human
sAC gene ADCY10 contains 33 exons covering approximately 104 kb
on chromosome 1q23.3-q24 [2,3] and encodes different sAC isoforms,
localized in the nucleus, cytoplasm andmitochondria, with distinct tissue
functions [4–16]. Two heterologous sAC catalytic domains (C1 and C2)
are known and up to 20-fold higher cAMP-forming activity has been re-
ported for the truncated ~50 kDa sAC isoformcompared to the full-length
form (see review by C. Steegborn in this issue for a schematic representa-
tion) [1]. The sAC full-length form contains an additional non-catalytic,
C-terminal, autoinhibitory region which functions to lower the enzyme's
Vmax without altering its substrate afﬁnity [17]. From an evolutionary
point of view, the catalytic sAC domains show higher conformity with
cyanobacterial adenylyl cyclase than with mammalian transmembrane
adenylyl cyclases (tmACs) [18], underlining its unique rank among
the otherwise homologous enzymes. The C-terminal end of the sAC
full-length form comprises several putative regulatory domains, includ-
ing an autoinhibitory region, a canonical P-loop, and a leucine zipperoluble adenylyl cyclase in health
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51 83 46979.
.sequence [19]. sAC is an evolutionarily conserved bicarbonate sensor
[18,20] and three other important intracellular messengers, namely
CO2, ATP, and Ca2+ have been reported to regulate sAC [18,21,22].
Due to the broad range of cellular processes that potentially involve
sAC but also other adenylyl cyclases, the exact role of sAC is only partly
understood. This review will focus on sAC in renal and vascular health
and disease, the role of sAC in aldosterone signaling and nuclear sAC
as a transcriptional regulator [8,23].
2. Aldosterone
The circulating steroid hormone aldosterone is predominantly pro-
duced in the cortex of the adrenal gland [24] and was ﬁrst isolated and
characterized in 1953 [25]. Aldosterone plays a central role in the regula-
tion of blood pressuremainly by acting on the epithelial sodium channel
(ENaC) in epithelial cells of the renal distal tubule, increasing sodium
reabsorption essential for the maintenance of body salt and water
homeostasis [26]. The key regulators of aldosterone production are the
adrenocorticotropic hormone (ACTH), potassium and angiotensin II
(Ang II) with calcium as a critical mediator [27]. Ang II is a product of
the complex systemic and evolutionarily well conserved renin–angio-
tensin–aldosterone system (RAAS), which is the principal volume-
regulatory effector in mammals and a major regulator of blood pressure
in humans (Fig. 1) [28]. The key effector precursor molecule of the
RAAS is angiotensinogen, a protein produced in the liver [29]. The unique
kidney-derived aspartyl protease renin, produced by the juxtaglomerular
apparatus, constitutes the rate-limiting and regulating step and cleaves
angiotensinogen to a small peptide of 10 amino acids termed angiotensin
Fig. 1. Regulation of aldosterone secretion and systemic aldosterone effects. Schematic representation of the major components of the renin–angiotensin–aldosterone system (RAAS).
Angiotensinogen of the liver is hydrolyzed by kidney-derived renin in the blood. The resulting angiotensin I is processed by the angiotensin converting enzyme (ACE), which is produced
by lung and kidney to the highly active effector peptide angiotensin II. Angiotensin II regulates the expression of the adrenocorticotropic hormone (ACTH) in the pituitary gland, thirst
sensation, sympathetic activity andmediates vasoconstriction. In the adrenal gland, angiotensin II stimulates the release of aldosterone,which regulates Na+/Cl− reabsorption and K+ se-
cretion in the nephron. Elevated levels of aldosterone may lead to arterial stiffness, cardiac remodeling and hypertension. Deleterious aldosterone actions can be antagonized by clinically
used mineralocorticoid receptor antagonists (MRAs) with nephroprotective, vasoprotective and cardioprotective effects.
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pulmonary endothelium)-derived matrix metalloproteinase angiotensin
converting enzyme (ACE) subsequently cleaves Ang I to the highly active
effector peptide Ang II, which in turn releases aldosterone from the
adrenal cortex [28]. In the brain, the RAAS-induced Ang II stimulates
thirst and salt appetite [31]. Besides the strong impact on blood pressure
and hypertension [32], RAAS dysregulation with increased aldosterone
secretion has been associatedwith chronic kidney disease (CKD) and car-
diovascular disease (CVD), including endothelial dysfunction and arterial
stiffness [33–39]. The important role of individual components of the
RAAS in the development of hypertension has also been underlined by
ﬁndings on the genetic and genomic level. Genes of the RAAS such as
the aldosterone synthase gene (CYP11B2), themineralocorticoid receptor
(MR) gene (NR3C2), the angiotensinogen gene (AGT) and genes that
mediate or regulate renal sodium handling such as ENaC (SCNN1B/G)
subunits have been identiﬁed to causemonogenic forms of hypertension
[30,40,41] and have been reported from genome-wide association
studies to be associated with blood pressure phenotypes [reviewed
by 42]. Despite local aldosterone expression in the adrenal glands,
extra-adrenal production of aldosterone by the aldosterone synthase
CYP11B2 has been identiﬁed in the heart, blood vessels, and brain
[43].3. The mineralocorticoid receptor (MR)
Aldosterone exerts its effects via theMR (nuclear receptor subfamily
3, group C, member 2; NR3C2), which belongs to the nuclear receptor
superfamily and functions as a ligand-dependent transcription factor
[44]. The MRmediates aldosterone effects on a variety of target tissues,
including the distal tubule of the kidney, the cardiovascular and central
nervous systems, the distal colon, the skin and sweat glands, as well as
brown adipose tissue [45,46]. MR selectivity is regulated on multiple
levels and severalmechanisms are involved to generate distinctMR iso-
forms and protein variants [reviewed by 47]. In humans, alternative
transcription of 5′-untranslated exons 1alpha and 1beta is known to
generate two different mRNA isoforms, hMRalpha and hMRbeta and
at least two different protein variants,MRAandMRBhave been reported,
which display distinct transactivation capacities in vitro. In addition,
alternative MR-splicing occurs and post-translational modiﬁcations of
the MR including phosphorylation, acetylation, ubiquitination and
sumoylation have been identiﬁed [47]. While the exact function of MR
isoforms and post-translational modiﬁcations is still under debate,
these mechanisms are likely to affect MR transcriptional regulation and
MR interaction with target molecules and coactivators as well as MR
turnover and subcellular trafﬁcking. Berger et al. underlined the
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tion ofMR-deﬁcientmice [48].MR-deﬁcientmice showedhyperkalemia,
hyponatremia and a strong increase in renin, Ang II, and aldosterone
plasma levels with symptoms of pseudohypoaldosteronism. Increasing
evidence from in vitro, in vivo and clinical studies suggests that in addi-
tion to its role in the regulation of sodium handling, functional MR is
expressed in a broad range of non-epithelial tissues, in particular the
cardiovascular system, contributing to hypertension, vascular inﬂamma-
tion, remodeling and atherogenesis [49]. Strong evidence for the delete-
rious actions of MR in the vasculature can be derived from smooth
muscle cell-speciﬁc MR-deﬁcient mice, which lack many aspects of
cardiovascular aging, such as increased blood pressure and blood pres-
sure responsiveness to Ang II, cardiac hypertrophy and increased Ang
II-dependent vasoconstriction [50]. Using this smooth muscle cell-
speciﬁc MR-deﬁcient model, it has recently been demonstrated that
vascular smooth muscle MR is essential for injury-induced vascular
ﬁbrosis, for aldosterone-induced vascular remodeling even under phys-
iological aldosterone levels and for enhanced vascular remodeling in re-
sponse to aldosterone excess [51]. In addition, Galmiche et al. showed
that vascular smooth muscle MR is required for increased arterial stiff-
ness in response to aldosterone and high salt-induced hypertension
[52]. MR-mediated signaling also affects vascular endothelial cells, in
that it modulates endothelial stiffness and thus endothelial function in-
cluding the expression of the vasodilator nitric oxide (NO), regulating
the vascular tone [53–56]. In addition to the ‘classical’ genomic aldo-
sterone effects, rapid and non-genomic MR-dependent aldosterone
actions, independent of transcription and translation, have been report-
ed in the renocardiovascular system [57–59]. Deleterious non-genomic
MR actions may lead to endothelial dysfunction, inﬂammation, as
well as cardiac remodeling [reviewed by 59]. Notably, rapid effects
of aldosterone have been suggested to be linked to activation of
adenylyl cyclases and cAMP production [58,60,61]. Since aldosterone
and the glucocorticoid cortisol have a comparable afﬁnity for theMR, an
additional mechanism exists to confer aldosterone-speciﬁc actions. The
‘gatekeeper’ enzyme 11beta-hydroxysteroid dehydrogenase (11beta-
HSD) leads to the conversion of active cortisol to receptor-inactive
cortisone so that aldosterone gains access to the MR [62]. Despite
broad acceptance of this concept, results from in vivo binding studies
suggest that the mechanism involving 11beta-HSD may be far more
complex [63]. It seems that 11beta-HSD is not efﬁcient in reducing the
cortisol level to the required threshold and glucocorticoids can occupy
but not activate the MR in the presence of 11beta-HSD. Thus, an addi-
tional (rather than alternative) mechanism has been suggested [64], in-
volving 11beta-HSD-derived NADH, which is a potential transcriptional
inhibitor [65] and might keep glucocorticoid-occupied MR in an inac-
tive state.
4. Mineralocorticoid receptor antagonists (MRAs)
4.1. Clinical relevance
Large prospective cross-sectional studies have reported that circulat-
ing aldosterone levels are independently associated with cardiovascular
morbidity and mortality [66–68]. These studies also suggest that even
aldosterone concentrations within the ‘normal’ range could result in
clinically relevant MR activation, which may be prevented via MR sig-
naling blockade by MRAs to prevent long-term pathophysiological
changes. The ﬁrst MRA, spironolactone, was developed over 50 years
ago with principal use in primary and secondary hyperaldosteronism.
Spironolactone was followed by eplerenone, which is less potent but
MR-selective [69] with shorter half-life and inactive metabolites.
Today, MRAs are guideline-recommended drugs for patients with
moderate to severe heart failure (HF) [70]. Large clinical trials including
the Randomized Aldactone Evaluation Study (RALES) [71] and the
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efﬁcacy
and Survival Study (EPHESUS) [72], demonstrated that MRAs cansigniﬁcantly reduce morbidity and mortality in HF patients. These trials
were followed by the Eplerenone in Mild Patients Hospitalization and
Survival Study in Heart Failure (EMPHASIS-HF), which included pa-
tients with mild HF and documented the efﬁcacy and safety of MRAs
in these patients [73]. Notably, the protective effect of spironolactone
was clearly demonstrated in the RALES study, although only slightly
elevated circulating aldosterone levels were observed [49]. This may
be explained by the fact that in conditions of tissue damage, in contrast
to normal physiological conditions, glucocorticoids become functional
MR agonists [64].
Aldosterone-induced and blood pressure-independent renal injuries
such as renal inﬂammation, renal ﬁbrosis, proteinuria aswell as glomeru-
lar and podocyte injury have also been identiﬁed as potential therapeutic
uses of MRAs [74]. Consistently, MRAs have been suggested as a ther-
apeutic strategy for patients with CKD [75]. Current clinical guidelines
have, however, included cautionary notes for the prescription of MRAs
in CKD patients. While the RALES investigators included HF patients
with serum creatinine concentrations up to 2.5 mg/dl, the incidence of
hyperkalemia was low [71]. A subsequent review of ‘real-world’ practice
demonstrated a signiﬁcant increase in hyperkalemia when the combina-
tion of RAAS blockade andMRAs had been prescribed [76]. This creates a
therapeutic dilemma in patients with HF and CKD, as MRAs might be
beneﬁcial in preventing mortality due to HF but may have considerable
side effects especially in patientswith low estimated glomerular ﬁltration
rate (eGFR). Therefore, low-dose MRAs in patients with reduced kidney
function (GFR b 45 ml/min/1.73 m2; GFR b 30 ml/min/1.73 m2 not indi-
cated) and close monitoring of potassium levels are recommended [77].
MRAs (i.e. spironolactone) are also recommended in patients with
therapy-resistant hypertension as an additional therapeutic option [69].
4.2. Mechanism of action
Spironolactone is effective at considerably low doses of 10 nM [78,
79], which has led to the assumption that it is acting as an inverse MR
agonist rather than a true MRA [64]. It might be due to this attribute
that the cardioprotective effects and exact molecular mechanisms of
spironolactone besides its function of ‘blocking’MR signaling are still in-
completely understood [80]. It seems conceivable that MRAs have a
broad range of pharmacological effects since MR-dependent signaling
is diverse and a multitude of downstream target genes exists. Notably,
data fromour lab suggests that spironolactone inhibits the translocation
of sAC into the nucleus in renal and endothelial cells (own unpublished
data). This observation provides an essentially new basis to discuss po-
tential MRA actions.
5. sAC in the kidney
5.1. sAC and bicarbonate
While the general role of adenylyl cyclases in salt andwater homeo-
stasis [reviewed by 81] and in renal cAMP formation [reviewed by 19] is
well established, detailed information on the individual and speciﬁc
functions of the diverse adenylyl cyclase enzymes is sparse. A broad
range of tmACs and the sAC are expressed in the kidney, which yields
a high number of potential cellular cAMP sources [82]. In a considerable
number of experiments, the effects of cAMP on hormonal (i.e. mineralo-
corticoid or glucocorticoid) receptor signaling have been analyzed using
synthetic cAMP derivatives or forskolin [reviewed by 83]. However,
these experiments were not designed to reveal the in vivo cAMP origin
(i.e. the speciﬁc adenylyl cyclase isoform).
sAC is different compared to other adenylyl cyclases with respect to
certain activators, which allows for the allocation of cellular functions
and pathophysiological processes to this enzyme. An early but indirect
evidence for sAC activity in the kidney was reported in a study that
described bicarbonate-stimulated cAMP forming activity in rat kidney
homogenates [84]. The origin of the cAMP remained elusive until sAC
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presented by Pastor-Soler et al. indicated that sAC is involved in the reg-
ulation of renal proton secretion and a potential sensor for monitoring
acid–base homeostasis by responding to bicarbonate concentration
[85,86]. The groupprovided evidence that sAC-mediated increases in in-
tracellular cAMP levels resulted in plasma membrane accumulation of
vacuolar proton pumping ATPase (V-ATPase), a protein involved in
renal proton secretion [84]. By immunoﬂuorescence of normal rat
kidney cortex, Paunescu et al. detected colocalization of sAC and the
V-ATPase in the apical and basolateral plasma membrane of alpha-
and beta-intercalated cells (ICs), which regulate bicarbonate reabsorp-
tion and proton (alpha-ICs) or bicarbonate secretion (beta-ICs) [87].
These experiments also suggest that sAC, despite its general soluble
character and thus predominant cytoplasmic localization, is concentrated
in functional complexes under certain physiological conditions. Interest-
ingly, the sAC-dependent V-ATPase mobilization has been discussed as
part of an evolutionary conserved mechanism for pH sensing involving
sAC [88], since a similar mechanism of pH homeostasis has been de-
scribed in shark [89]. In ICs, sAC seems to be localized in domains associ-
ated with the apical or basolateral plasma membrane in close proximity
to its potential target molecule V-ATPase and coimmunoprecipitation
suggested that the V-ATPase interacts speciﬁcally with the 50 kDa sAC
isoform. It seems conceivable that subcellular sAC concentrations in pro-
cesses related to bicarbonate homeostasis might be regulated by scaffold
proteins which assemble multiple signaling enzymes, receptors or ion
channels into functional complexes [90]. This is also supported by studies
which used a cellular cAMP monitoring system based on the expression
of sAC to show that phosphodiesterases and A-kinase anchoring proteins
(AKAPs) are involved in nuclear protein kinase A (PKA) responses [91], as
well as the observation that sAC compartmentalizes in signalingmicrodo-
mains [92].
In 2013, researchers of the Chronic Renal Insufﬁciency Cohort (CRIC)
study reported an association between serum bicarbonate misbalance
and adverse outcomes in patientswith CKD, in that a nonlinear relation-
ship between bicarbonate levels and HF outcomes existed [93]. In a sub-
set of participants without CVD at baseline, a 22% higher risk of HF was
detected for every 1-mEq/L increase in serum bicarbonate level
N24 mEq/L. In addition, serum bicarbonate level was independently as-
sociated with renal outcome deﬁned as progression to end-stage renal
disease or 50% eGFR reduction, even after adjustment of baseline values
for eGFR and proteinuria [93]. The molecular mechanisms underlying
these observations are not fully understood, but recent studies sug-
gested that CKD patients without metabolic acidosis nevertheless have
H+ retention that increases plasma aldosterone levels, possiblymediating
GFR decline [94]. Notably, aldosterone has been reported to increase
V-ATPase-dependent proton secretion in intercalated cells of the outer
medullary collecting duct, which may contribute to acid secretion and
control of systemic acid–base homeostasis [95]. It seems conceivable
that both aldosterone and bicarbonate may affect renal processes via
sAC-dependent mechanisms.
5.2. sAC and calcium
In addition to the sensitivity of sAC to bicarbonate, calcium has been
identiﬁed as a modulator of sAC activity, connecting sAC to bone mineral
metabolism and the complexmechanism of systemic calcium regulation.
Calcium, in contrast to bicarbonate, increases the sAC afﬁnity for
ATP-Mg2+ [21]. Therefore, calcium and bicarbonate synergistically
activate sAC and small changes of either calcium or bicarbonate
could lead to signiﬁcant changes in cellular cAMP levels [21]. Several
sAC splice variants have been detected in osteoclasts and osteoblasts
[96] and experiments using the sAC inhibitor 2CE or anti-sAC-siRNA
suggested that sAC is involved in inhibition of osteoclast differentiation
at high bicarbonate levels [13]. This observation indicates that
bicarbonate-sensing sAC is a physiologically relevant regulator of bone
formation and/or reabsorption even if the exact role of sAC inosteoclastogenesis is still under debate since similar inhibitory effects
during bicarbonate-free conditions have also been observed [19]. The
involvement of sAC in systemic calcium regulation might be of clinical
relevance since progression of impaired renal function is accompanied
by increasing abnormalities of serum calcium, phosphate, parathyroid
hormone (PTH) and vitamin D metabolites [77]. Robust data are avail-
able for elevated PTH levels, which have been associated with all-
cause and cardiovascular mortality in patients with coronary artery dis-
ease [97] and end-stage renal disease [98]. Dysregulation of calciumand
phosphate has been suggested to occur relatively later in the course of
CKD compared to detectable changes of vitamin D and PTH and current
guidelines recommend measuring serum levels of calcium, phosphate
and PTH at least once in patients with GFR b 45 ml/min/1.73 m2 to de-
termine baseline values [77].
PTH is secreted by the parathyroid glands and acts to increase calcium
levels in the blood by a complex mechanism in several target organs. In
the kidney, PTH enhances reabsorption of calcium and magnesium,
while it triggers a decrease in phosphate reabsorption thus leads to in-
creased phosphate excretion in the urine [99]. In addition, PTH regulates
the renal production of active 1,25-dihydroxy vitamin D, which in turn
enhances the intestinal saturable active transport of calcium [100]. PTH
also stimulates bone reabsorption resulting in calcium and phosphate re-
lease. In addition to low serum calcium levels as stimulus for PTH secre-
tion, the clinically relevant impact of the RAAS on PTH secretion has
been discussed [101] based on interventional studies including Ang II
and aldosterone [102]. The study by Brown et al. also suggested that
PTH may be regulated by aldosterone since reduced PTH and raised
serum calcium levels were observed under MRA therapy [102]. The clin-
ical relevance of this observation has been underlined by introduction of
the EPATH (effect of eplerenone on parathyroid hormone levels in pa-
tients with primary hyperparathyroidism) study, which was designed
to evaluate the inﬂuence of long-term MRA treatment in a population
with primary hyperparathyroidism [99].
Several studies proposed that aldosteronemay cause calciumwasting,
particularly in the setting of dietary salt excess, although conﬂicting re-
sults have been reported and the underlying mechanisms remain largely
unknown [103–107]. One potential explanation for the inconsistent re-
ports on aldosterone-induced calcium wasting might involve individual
genetic predispositions. Interestingly, a few reports on association of the
ADCY10 gene locuswith calcium excretion exist, providing a potential ge-
netic link between calcium, kidney and the vasculature. Initially, linkage
analyses in three families with absorptive hypercalciuria have indicated
an association with the ADCY10 locus on chromosome 1q23.3-q24 [2].
Deep sequencing of genes located at this chromosomal site identiﬁed an
association between hypercalciuria and six single nucleotide polymor-
phisms (SNPs) in the ADCY10 gene, in that two SNPs were only detected
in hypercalciuric cases. Bone mineral density (BMD) was lower as the
number of associated alleles increased and osteoporosis was more
frequent in individuals with at least one ADCY10 SNP [3], conﬁrming the
relevance of this gene for calcium homeostasis. Based on a detected
linkage of spinal BMD to chromosome 1q [108,109] and the reportsmen-
tioned above, Ichikawa et al. tested ADCY10 as a candidate gene for asso-
ciationwith BMD in healthyWhite Americans and detected amodest but
signiﬁcant effect of the ADCY10 genotypes on BMD [110]. The results have
recently been replicated by Cao et al. using an integrative data anal-
ysis approach to identify genes associated with osteoporosis [111].
These individual reports suggest that variations at the ADCY10
locus may cause mild calcium wasting in urine, which could lead to
the subsequently lowered BMD over time. The identiﬁcation of the
sAC coding gene ADCY10 in these studies promote sAC from a simple
bystander to a disease-causing candidate, which affects calcium
homeostasis. Further studies are needed to evaluate whether the ob-
served associations might also play a role in the calcium–phosphate–
PTH–vitamin D axis in vascular calciﬁcation and CKD or aldosterone-
dependent calcium wasting processes. These studies may also provide
evidence if modulation of both sAC activity and aldosterone-induced
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aldosterone.
5.3. sAC, ENaC and the Na+/K+-ATPase
The unique nature of sAC as bicarbonate sensor and the discovery of
the speciﬁc pharmacological sAC inhibitor KH7 [112] allow for the
distinction of molecular processes which involve sAC [113]. These spe-
ciﬁc sAC characteristics have been used and extended most recently
by Sample et al. who attached a monomeric red ﬂuorescent protein to
the catalytically active form of sAC (sACt) [18] in combination with
different localization signals to target subcellular sACt and thus monitor
and manipulate cellular cAMP dynamics [91]. In 2008, Hallows et al.
postulated that sAC may be an important regulator of sodium reabsorp-
tion in the kidney [5]. Using the speciﬁc sAC inhibitor KH7 and anti-
sAC-siRNA, the group provided evidence that sAC inhibition leads to
impaired basal trans-epithelial sodium currents in mouse cortical
collecting duct cells (Fig. 2). This indicated a role for sAC in aldosterone-
stimulated trans-epithelial sodium currents that depend on both ENaCFig. 2. Effects of aldosterone and sAC on renal epithelial and vascular endothelial cells. Renal sod
heterotrimeric epithelialNa+ channel (ENaC),whichpromotes reabsorption of sodium fromuri
reduced circulating volume, leading to subsequent ENaC activation in the collecting duct (CD)
pool to the apicalmembrane. In renal epithelial cells, basolateral Na+/K+-ATPase provides the e
active in the distal tubule (DT) and thick ascending limb (TAL). In the vascular endothelium, the
the presence of elevated aldosterone and Na+ concentrations. Aldosterone also affects the ac
decreased production of nitric oxide (NO) with impaired vascular smooth muscle (VSMC) ce
cells Na+/K+-ATPase and ENaC expression is regulated by aldosterone and sAC at the transcri
sAC activity. In endothelial cells, sAC is involved in the regulation of actin ﬁber composition an
thelium can be prevented by the mineralocorticoid receptor antagonist (MRA) spironolactoneand the Na+/K+-ATPase. Sodium reabsorption from urine in the distal
nephron is controlled by aldosterone via surface expression and activity
of the apical heterotrimeric ENaC [26]. With decreasing blood pressure
or reduced circulating volume, aldosterone secretion increases, leading
to subsequent ENaC activation in the collecting duct. The electrochemical
driving force for ENaC is provided by the Na+/K+-ATPase [114]. The
Na+/K+-ATPase is an integral membrane protein composed of an
alpha and beta subunit, essential for maintaining the electrochemical
gradients of Na+ and K+ across the plasma membrane [115]. Under
physiological conditions, the Na+/K+-ATPase exchanges three intercel-
lular Na+ for two extracellular K+ at the expense of one ATP. Besides
the important mechanism of feedback control in sodium handling
by intracellular Na+, aldosterone actions independent of Na+ on
ENaC and Na+/K+-ATPase exist [114,115], which involve regulation
on the transcriptional level. Based on the observations of Hallows
et al. [5], we have recently identiﬁed a regulatory role of sAC on
ENaC and Na+/K+-ATPase gene expression in that basal ENaC and
Na+/K+-ATPase protein levels were signiﬁcantly reduced by 24 h appli-
cation of KH7 in renal epithelial cells in vitro [8]. This observation ofium handling is controlled by aldosterone via surface expression and activity of the apical
ne in thedistal nephron. Aldosterone secretion increaseswith decreasing blood pressure or
. Non-genomic aldosterone signaling stimulates rapid ENaC translocation from a vesicular
lectrochemical driving force for apical ENaC. Besides the CD, Na+/K+- ATPase is also highly
expression of ENaC andNa+/K+-ATPase have been associatedwith endothelial stiffness in
tin ﬁber composition of endothelial cells, which leads to altered mechanosensitivity and
ll relaxation and reduced vasodilation. In both, renal epithelial and vascular endothelial
ptional level. In CD cells, aldosterone-stimulated transepithelial Na+ current depends on
d endothelial stiffness. Deleterious aldosterone effects in the renal CD and vascular endo-
and the sAC inhibitor KH7.
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sion also provided insight into a shared mechanism between the kidney
and the vascular endothelium (Fig. 2).
6. sAC in the vascular endothelium
In recent years, endothelial ENaC and theNa+/K+-ATPase have been
identiﬁed as important regulators of endothelial function [54,55,116].
Both, ENaC and the Na+/K+-ATPase, are involved in the salt-sensitive
regulation of mechanical properties of the endothelial cell and thus
affect endothelial stiffness which is crucial for the balance between en-
dothelial function and dysfunction (Fig. 2). Aldosterone is a potentmod-
ulator of endothelial stiffness by altering the cellular actin composition
and the cell's sensitivity to extracellular sodium changes [117,36]. The
altered nanomechanic properties of endothelial cells in vascular endo-
thelium determine nitric oxide (NO) release in that soft endothelial
cells release more vasodilating NO than stiff endothelial cells [36],
whereas the latter can be seen as the hallmark for endothelial dysfunc-
tion [118]. The endothelium-derived NO directly acts on vascular
smooth muscle cells (Fig. 2), leading to vasodilation and decreased vas-
cular tone [36,54,55]. Thus, the vascular endothelium is supposed to
play a crucial role inmaintaining overall arterial stiffness [119]. Patients'
arterial stiffness can be assessed by pulse wave velocity (PWV) mea-
surement and increased PWV is a strong and independent predictor of
cardiovascular morbidity and all-cause mortality [120,121]. Besides its
effects on endothelial actin ﬁber composition and NO production, aldo-
sterone also regulates endothelial stiffness by the insertion of ENaC into
the plasma membrane of the vascular endothelium [55,122,123], a
mechanism ﬁrst detected in renal epithelial cells. Consistently, MRAs
have been shown to prevent overall arterial stiffness [119] and the ap-
plication of spironolactone has been reported to prevent the ‘stiff endo-
thelial cell syndrome’ [124]. Endothelial stiffness can be assessed in vitro
and ex vivo by using the atomic forcemicroscope (AFM) as a nanosensor
[56,118]. Our group has recently reported that the expression of genes
regulating endothelial stiffness depends on sAC [8]. Our observations
suggest that sAC is involved in the regulation of the Na+/K+-ATPaseFig. 3. Effects of sAC andMR on transcriptional regulation. Activation of the mineralocorticoid r
hormone response elements (HRE). MR-dependent transcriptional activation can be prevented
vates protein kinase A (PKA), which phosphorylates the cAMP response element-binding prot
ments (CRE). The scaffold protein A-kinase anchor protein (AKAP) forms a regulatory comp
transcription.alpha and beta subunit as well as ENaC alpha in endothelial cells. AFM
measurements detected signiﬁcant endothelial softening after treat-
ment of endothelial cells in vitrowith KH7. Furthermore, the signiﬁcant
aldosterone-induced stiffening of mouse aorta endothelial cells was
prevented by sAC inhibition ex vivo and KH7-treatedmouse aorta endo-
thelial cells were signiﬁcantly softer than untreated cells. These results
indicated that sAC inhibition via the observed effects on gene expres-
sion, even in the presence of aldosterone, translate into an overall endo-
thelial softening.
6.1. Transcriptional regulation by sAC
Interestingly, chromatin immunoprecipitation after sAC inhibition
revealed altered interactions between transcription factors, including
cAMP response element-binding protein (CREB) and promoter regions
with active endothelial cAMP responsive elements (CRE) [8]. This obser-
vation suggests that sAC might be part of a transcriptional module in-
volved in the regulation of CRE-promoters (Fig. 3). cAMP production by
nuclear sAC activates PKA, which subsequently phosphorylates CREB,
altering transcription by binding to CRE sites. Sample et al. provided
evidence that the scaffold protein AKAP forms a regulatory complex
with PKA, potentially involving CREB and sAC [91].
Besides its effects on CRE-promoters, wewere also able to show that
sAC inhibition leads to impaired transcriptional activity of hormone re-
sponse element (HRE) promoter activity, which is activated by aldoste-
rone [8]. This illustrates that sAC is involved in both the cAMP/CREB and
theMR pathway (Fig. 3), with a wide range of potentially regulated tar-
get genes. This is of particular interest as several studies suggested a
functional interaction between aldosterone/MR and the cAMP/CREB
signaling pathway [83]. One essential gene potentially regulated by
sAC-dependent signaling is the serum/glucocorticoid regulated kinase-
1 (SGK-1). SGK-1 is a classical MR target gene that mediates enhanced
ENaCexpression and therefore sodium transport [125] and is potentially
stimulated by cAMP in mouse distal convoluted tubule cells [126]. sAC
has also been implicated in the Rho/Rac signaling pathway, which is
known to regulate cell morphology by actinmodulation. Rac1 is a potenteceptor (MR) by aldosterone results in nuclear MR accumulation and increased binding to
by mineralocorticoid receptor antagonists (MRAs). cAMP production by nuclear sAC acti-
ein (CREB). Phosphorylated CREB alters transcription by binding to cAMP responsive ele-
lex with PKA, sAC and CREB. The sAC inhibitor KH7 impairs CRE- and HRE-dependent
2607B. Schmitz et al. / Biochimica et Biophysica Acta 1842 (2014) 2601–2609activator ofMR signal transduction, in that Rac1 increasesMRnuclear ac-
cumulation with subsequent enhancement of MR-dependent promoter
activity [127]. Notably, sAC has been described as a unique activator of
the small G protein Rap1 [9]. The sAC-dependent CRE-promoter activa-
tion is also interesting in light of the ﬁnding by Krishnan et al. [128].
The group reported that PTH activates CRE-promoter transcription. Pre-
liminary data suggest that PTH-dependent activation of CRE-promoters
may be prevented by sAC inhibition (own unpublished data).7. Conclusion
There is current evidence that sAC is a regulator of aldosterone
signaling in the kidney and vascular endothelium. In renal tubular
cells, aldosterone-stimulated transepithelial sodium current depends
on sAC activity. In vascular endothelial cells, sAC is involved in the reg-
ulation of actin ﬁber composition and endothelial stiffness. sAC may be
an important modulator of pathophysiological conditions in CKD and
CVD patients, including endothelial dysfunction and chronic arterial
stiffness. Effects of experimental sAC inhibitors such as KH7 show simi-
larities to the effects of clinically used MRAs and are potential novel
compounds for the prevention of deleterious aldosterone effects in
CKD and CVD. Additional evidence fromexperimental and clinical studies
is needed to conﬁrm sAC as a potential therapeutic target in these com-
mon disorders.Conﬂict of interest
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